Document Detail

Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.
MedLine Citation:
PMID:  15331798     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Pharmacological modulation of complement activation recently has been postulated as a therapeutic target in the treatment of neurological injury. We hypothesized that pexelizumab, a humanized scFv monoclonal antibody directed against the C5 complement component, would limit deficits in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. METHODS: The Phase II Pexelizumab study was a 914-patient, double-blind, placebo-controlled, 65-center study of patients undergoing coronary artery bypass graft surgery. Patients were randomized to pexelizumab bolus, bolus plus infusion, or placebo. Neurological and neurocognitive functions were assessed as secondary endpoints at baseline and on postoperative days (POD) 4 and 30. Cognitive deficits were assessed with multivariable tests accounting for baseline cognition, age, diabetes, years of education, sex, elevated creatinine, history of myocardial infarction, neurological disorder or congestive heart failure, and cardiopulmonary bypass time. RESULTS: Pexelizumab had no statistically significant effect on the primary composite endpoint or on overall cognition. When domain specific effects were examined, a decline of at least 10% in the visuo-spatial domain was observed on POD 4 in 56% of patients receiving placebo compared with 40% receiving pexelizumab by bolus and infusion (P=0.003). Similarly, on POD 30, a 10% decline was present in 21% of patients in the placebo group versus only 12% of the drug bolus plus infusion group (P=0.016). No differences were seen between treatment groups in any of the other domains. CONCLUSIONS: Pexelizumab administration for 24 hours perioperatively had no effect on global measures of cognition but may reduce dysfunction in the visuo-spatial domain.
Joseph P Mathew; Stanton K Shernan; William D White; Jane C K Fitch; John C Chen; Leonard Bell; Mark F Newman
Related Documents :
10355398 - Management of exsanguinating hemoptysis during cardiopulmonary bypass.
3259728 - Coronary reoperations.
15673848 - Segmental myocardial wall motion during minimally invasive coronary artery bypass graft...
24817898 - Time-course of the effects of qsyq in promoting heart function in ameroid constrictor-i...
20930678 - The value of angiogenic therapy with intramyocardial administration of basic fibroblast...
8095738 - Therapy of left ventricular dysfunction: implications of recent therapeutic trials and ...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2004-08-26
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  35     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-24     Completed Date:  2005-03-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2335-9     Citation Subset:  IM    
Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage,  therapeutic use*
Coronary Artery Bypass*
Double-Blind Method
Middle Aged
Neuroprotective Agents / administration & dosage,  therapeutic use*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Neuroprotective Agents; 0/h5G1.1-scFv

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke:...
Next Document:  Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS).